A Time‐Programmed Release of Dual Drugs from an Implantable Trilayer Structured Fiber Device for Synergistic Treatment of Breast Cancer. Issue 9 (19th July 2019)

• Record Type: Journal Article
• Authors: Li, Xilin; He, Yang; Hou, Jianwen; Yang, Guang; Zhou, Shaobing
• Is Part Of: Small. Volume 16:Issue 9(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-07-19
• Subjects: combination chemotherapy -- fibers -- microfluidic‐electrospinning -- time‐programmed release -- trilayer structures; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.201902262
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: Combination chemotherapy with time‐programmed administration of multiple drugs is a promising method for cancer treatment. However, realizing time‐programmed release of combined drugs from a single carrier is still a great challenge in enhanced cancer therapy. Here, an implantable trilayer structured fiber device is developed to achieve time‐programmed release of combined drugs for synergistic treatment of breast cancer. The fiber device is prepared by a modified microfluidic‐electrospinning technique. The glycerol solution containing chemotherapy agent doxorubicin (Dox) forms the internal periodic cavities of the fiber, and poly(l ‐lactic acid) and poly(ε‐caprolactone) containing the angiogenesis inhibitor apatinib (Apa) form the double walls of the fiber. Rapid release of Dox can be obtained by adjusting the wall thickness of the cavities, meanwhile sustained release of Apa is achieved through the slow degradation of the fiber matrix. After the fiber device is implanted subcutaneously near to the implanted solid tumor of mice, an excellent synergistic therapeutic effect is achieved through time‐programmed release of the combined dual drugs. The fiber device provides a platform to sequentially co‐deliver dual or multiple drugs for enhanced combined therapeutic efficacy. Abstract : An implantable trilayer structured fiber device is successfully developed through a modified microfluidic‐electrospinning technique, which has theability to release combined drugs in a time‐programmed mode. An excellent synergistic therapeutic effect on breast cancer can be achieved by the fast release of chemotherapy agent, causing tumor cell death; and a sustained release of vascular inhibitor, inhibiting tumor angiogenesis.